Oral vs Injectable — How Delivery Works
There is already an FDA-approved oral GLP-1 pill for weight loss — the Wegovy pill (oral semaglutide), approved December 2025. A second oral option with no food restrictions (orforglipron) is in the pipeline. Here is how the two delivery approaches differ, and why oral delivery took so long.
Quick read · 5 min
The Wegovy pill (semaglutide 25mg, once daily) was FDA approved December 22, 2025, and launched in the US in January 2026. It produces similar weight loss to the injection (~16.6% with full adherence in the OASIS 4 trial) at dramatically lower cost (~$149/month vs ~$1,350/month).
See semaglutide page for full details →- •An oral GLP-1 for weight loss (Wegovy pill) is now FDA-approved — available since January 2026
- •Injections go under the skin and bypass the stomach — once-weekly for most drugs
- •The Wegovy pill uses SNAC technology to get through the stomach — but requires a 30-min fasting window
- •Orforglipron (pipeline, FDA decision expected 2026) is a small-molecule pill with NO food restrictions
Based on clinical trials · No rankings · Every claim linked to source
Last reviewed: March 2026
Why oral GLP-1s are challenging
GLP-1 drugs like semaglutide and liraglutide are peptides — chains of amino acids, essentially small proteins. The digestive system is designed to break down proteins. When you swallow a peptide:
- ✕Stomach acid immediately begins denaturing (unfolding) the peptide structure
- ✕Pepsin (a stomach enzyme) starts cleaving the peptide chain
- ✕Even if it reaches the small intestine, intestinal enzymes further degrade it
- ✕What remains is largely amino acids — not an intact drug molecule
This is why subcutaneous injection has been the standard — it delivers the drug directly under the skin into the lymphatic system and bloodstream, bypassing the digestive system entirely. Subcutaneous semaglutide has approximately 42% bioavailability.
Solution 1: SNAC technology (oral semaglutide)
Oral semaglutide (Rybelsus) uses a chemical called SNAC (Sodium N-(8-[2-hydroxybenzoyl] amino) caprylate) to sneak the drug through the stomach wall. SNAC works through three mechanisms:
- 1pH buffering: SNAC locally raises the pH around the tablet, reducing pepsin activity — the enzyme that would otherwise destroy semaglutide.
- 2Monomerisation: Changes local polarity so semaglutide molecules stay separate (monomeric) rather than clumping — making them easier to absorb across the stomach lining.
- 3Membrane permeabilisation: SNAC embeds temporarily into stomach lining cells, making them more permeable to semaglutide molecules.
Bioavailability caveat: Oral semaglutide achieves less than 1% bioavailability vs ~42% for subcutaneous. A much higher dose is required orally (14mg tablet vs 2.4mg injection) to achieve comparable effect. It must be taken on an empty stomach with no more than 120ml (4oz) of water, at least 30 minutes before food.
Solution 2: Small molecule oral GLP-1s (orforglipron — pipeline)
Orforglipron (Eli Lilly, FDA decision expected 2026) takes a fundamentally different approach. Unlike oral Wegovy — which uses SNAC technology and requires a fasting window — orforglipron has no food or water restrictions at all. Rather than a peptide, it is a small molecule — a different class of drug entirely.
- •Protein structure — destroyed by stomach acid
- •Requires SNAC technology or injection
- •Strict food timing restrictions (oral)
- •Low oral bioavailability (<1%)
- •Naturally acid-stable — gut-resistant
- •No special technology needed
- •No food timing restrictions
- •Higher oral bioavailability
In the ATTAIN-1 trial (3,127 adults with obesity), participants taking orforglipron lost an average of 12.4% body weight at 72 weeks — comparable to injectable GLP-1s at similar timepoints. If approved, this would be the first truly convenient oral GLP-1 drug.